5alpha-Reductase Inhibitors Dampen L-DOPA-Induced Dyskinesia via Normalization of Dopamine D1-Receptor Signaling Pathway and D1-D3 Receptor Interaction

    September 2018 in “ Neurobiology of Disease
    Silvia Fanni, Simona Scheggi, Francesca Rossi, Elisabetta Tronci, Francesco Traccis, Roberto Stancampiano, Maria Graziella De Montis, Paola Devoto, Carla Gambarana, Marco Bortolato, Roberto Frau, Manolo Carta
    Image of study
    TLDR Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
    In the 2019 study, finasteride (FIN) and dutasteride (DUTA), both 5alpha-reductase inhibitors, were found to significantly reduce L-DOPA-induced dyskinesia (LID) in a rat model of Parkinson's disease without affecting the therapeutic effects of L-DOPA. DUTA was more effective at lower doses and did not impact motor activation, suggesting it could be a better option for controlling dyskinesia without compromising the benefits of L-DOPA. The study, which included groups of 7-13 rats, showed that these inhibitors prevented the upregulation of striatal dopamine D1 receptor-related signaling pathways and reduced the interaction between D1 and D3 receptors, indicating a potential new therapeutic target for dyskinesia in Parkinson's disease.
    Discuss this study in the Community →

    Research cited in this study

    8 / 8 results

    Related Community Posts Join

    6 / 1000+ results

      community Bryan Johnson just dropped his anti hair loss formula

      in Treatment  339 upvotes 9 months ago
      Bryan Johnson shared his hair loss treatment, which mainly relies on minoxidil and finasteride. Some users are skeptical of his results, while others appreciate his efforts in anti-aging and hair loss research.

      community Does finasteride/dutasteride reverse aging?

      in Chat  45 upvotes 1 month ago
      Finasteride and dutasteride can improve skin texture and reduce acne by lowering DHT but do not reverse aging. They may enhance skin and hair health for some, but can also cause side effects like dry skin and sexual dysfunction.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 2 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Similar Research

    5 / 1000+ results